Eribulin Mesylate Injection
Product Images NDC 68462-770

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 68462-770). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image1 (Image1)

Chemical structure of eribulin mesylate, the active ingredient in ERIBULIN MESYLATE injection. The diagram displays the molecular arrangement including rings, oxygen atoms, and sulfonic acid moiety.*

FDA Label Image

Image2 (Image2)

A survival curve graph showing the proportion of patients alive over time in months. It compares patients treated with eribulin mesylate injection (N=508) versus a control group (N=254). The graph depicts higher survival associated with eribulin mesylate treatment over a 36-month period, with patient numbers at risk listed below the x-axis.*

FDA Label Image

Image3 (Image3)

A survival probability Kaplan-Meier curve comparing eribulin mesylate and dacarbazine treatments. The graph displays survival probability over time in months, with the number of subjects at risk listed below for both treatment groups at various time points up to around 42 months.*

FDA Label Image

Image4 (Image4)

FDA Label Image

Image5 (Image5)

FDA Label Image

Image6 (Image6)

Label for Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) sterile solution, intended for intravenous use. The label indicates it is a single-dose vial distributed by Glenmark Pharmaceuticals Inc., USA. Storage instructions specify 25°C with permitted excursions and caution against freezing or refrigerating. Contains warnings for cytotoxic agent handling, with a barcode and lot/expiration date fields.*

FDA Label Image

Image7 (Image7)

Carton label for Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL), an intravenous sterile solution supplied as a single-dose vial. The label features the proprietary name, concentration, caution for cytotoxic agent status, and directions to discard unused portions. Distributed by Glenmark Pharmaceuticals Inc., USA, with storage instructions and barcode visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.